DexCom Statistics

Total Valuation

DexCom has a market cap or net worth of EUR 20.20 billion. The enterprise value is 19.69 billion.

Market Cap	20.20B
Enterprise Value	19.69B

Important Dates

The next confirmed earnings date is Thursday, April 30, 2026.

Earnings Date	Apr 30, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	385.87M
Shares Outstanding	n/a
Shares Change (YoY)	-1.75%
Shares Change (QoQ)	-2.09%
Owned by Insiders (%)	0.37%
Owned by Institutions (%)	97.10%
Float	383.95M

Valuation Ratios

The trailing PE ratio is 28.36 and the forward PE ratio is 24.13.

PE Ratio	28.36
Forward PE	24.13
PS Ratio	5.09
PB Ratio	8.64
P/TBV Ratio	8.95
P/FCF Ratio	22.02
P/OCF Ratio	16.46
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.27, with an EV/FCF ratio of 21.46.

EV / Earnings	27.64
EV / Sales	4.95
EV / EBITDA	19.27
EV / EBIT	25.33
EV / FCF	21.46

Financial Position

The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.51.

Current Ratio	1.88
Quick Ratio	1.53
Debt / Equity	0.51
Debt / EBITDA	1.17
Debt / FCF	1.30
Interest Coverage	49.83

Financial Efficiency

Return on equity (ROE) is 34.50% and return on invested capital (ROIC) is 33.98%.

Return on Equity (ROE)	34.50%
Return on Assets (ROA)	8.89%
Return on Invested Capital (ROIC)	33.98%
Return on Capital Employed (ROCE)	21.72%
Weighted Average Cost of Capital (WACC)	12.15%
Revenue Per Employee	359,333
Profits Per Employee	64,459
Employee Count	11,100
Asset Turnover	0.73
Inventory Turnover	3.18

Taxes

In the past 12 months, DexCom has paid 214.71 million in taxes.

Income Tax	214.71M
Effective Tax Rate	23.16%

Stock Price Statistics

The stock price has decreased by -16.59% in the last 52 weeks. The beta is 1.56, so DexCom's price volatility has been higher than the market average.

Beta (5Y)	1.56
52-Week Price Change	-16.59%
50-Day Moving Average	57.48
200-Day Moving Average	60.34
Relative Strength Index (RSI)	35.82
Average Volume (20 Days)	162

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.44

Income Statement

In the last 12 months, DexCom had revenue of EUR 3.97 billion and earned 712.28 million in profits. Earnings per share was 1.78.

Revenue	3.97B
Gross Profit	2.39B
Operating Income	776.58M
Pretax Income	926.99M
Net Income	712.28M
EBITDA	991.04M
EBIT	776.58M
Earnings Per Share (EPS)	1.78

Balance Sheet

The company has 1.70 billion in cash and 1.19 billion in debt, giving a net cash position of 512.98 million.

Cash & Cash Equivalents	1.70B
Total Debt	1.19B
Net Cash	512.98M
Net Cash Per Share	n/a
Equity (Book Value)	2.34B
Book Value Per Share	6.08
Working Capital	1.61B

Cash Flow

In the last 12 months, operating cash flow was 1.23 billion and capital expenditures -309.59 million, giving a free cash flow of 917.45 million.

Operating Cash Flow	1.23B
Capital Expenditures	-309.59M
Depreciation & Amortization	215.04M
Net Borrowing	-1.03B
Free Cash Flow	917.45M
FCF Per Share	n/a

Margins

Gross margin is 60.10%, with operating and profit margins of 19.56% and 17.94%.

Gross Margin	60.10%
Operating Margin	19.56%
Pretax Margin	23.35%
Profit Margin	17.94%
EBITDA Margin	24.96%
EBIT Margin	19.56%
FCF Margin	23.11%

Dividends & Yields

DexCom does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.75%
Shareholder Yield	1.75%
Earnings Yield	3.53%
FCF Yield	4.54%

Stock Splits

The last stock split was on June 13, 2022. It was a forward split with a ratio of 4.

Last Split Date	Jun 13, 2022
Split Type	Forward
Split Ratio	4

Scores

DexCom has an Altman Z-Score of 7.06 and a Piotroski F-Score of 6.

Altman Z-Score	7.06
Piotroski F-Score	6